Abstract
BACKGROUND: The discrepancy between glycosylated hemoglobin (HbA(1c)) and fasting plasma glucose (FPG) in clinical practice may be related to factors such as acute stress, renal dysfunction, and anemia, and its relationship with in-hospital outcomes is uncertain. The aim of this study was to investigate the association between the type of discrepancy between HbA(1c) and FPG and in-hospital outcomes in patients with acute coronary syndrome (ACS) and diabetes. METHODS: The Improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) project is a national, hospital-based quality improvement project with an ongoing database. Patients with ACS, diabetes and complete HbA(1c) and FPG values at admission were included. The consistent group included patients with HbA(1c) < 6.5% and FPG < 7.0 mmol/L or HbA(1c) ≥ 6.5% and FPG ≥ 7.0 mmol/L. The discrepancy group included patients with HbA(1c) ≥ 6.5% and FPG < 7.0 mmol/L (increased HbA(1c) group) or HbA(1c) < 6.5% and FPG ≥ 7.0 mmol/L (increased FBG group). RESULTS: A total of 7762 patients were included in this study. The numbers of patients in the consistent and discrepancy groups were 5490 and 2272 respectively. In the discrepancy group, increased HbA(1c) accounted for 77.5% of discrepancies, and increased FPG accounted for 22.5% of discrepancies. After adjusting for confounders, patients in the increased FPG group had a 1.6-fold increased risk of heart failure (OR, 1.62; 95% CI, 1.08-2.44), a 1.6-fold increased risk of composite cardiovascular death and heart failure (OR, 1.63; 95% CI, 1.09-2.43), and a 1.6-fold increased risk of composite major adverse cardiovascular and cerebrovascular events (MACCEs) and heart failure (OR, 1.56; 95% CI, 1.08-2.24) compared to patients in the increased HbA(1c) group. CONCLUSIONS: Patients with an increased FPG but normal HbA(1c) had a higher risk of in-hospital adverse outcomes than those with increased HbA(1c) but normal FPG. This result may indicate that when HbA(1c) and FPG are inconsistent in patients with ACS and diabetes, the increased FPG that may be caused by stress hyperglycemia may have a more substantial adverse effect than increased HbA(1c), which may be caused by chronic hyperglycemia. These high-risk patients should be given more attention and closer monitoring in clinical practice. TRIAL REGISTRY: Clinicaltrial.gov , NCT02306616 . Registered 29 November 2014.